Santen Pharmaceutical : Selected as a Member of Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment

September 19, 2017, Osaka, Japan - Santen Pharmaceutical Co., Ltd. ("Santen") today announced that Santen has been selected for the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), one of the world's foremost indices for socially responsible investment (SRI).

The DJSI family was jointly established between RobecoSAM AG (Switzerland) and S&P Dow Jones Indices LLC (United States) in 1999 as the first global SRI indices in the world and assesses the corporate sustainability performance based on economic, environmental and social points of view. In 2017, the DJSI Asia Pacific has selected 152 companies among the Asian region's top 600 companies.

Based on Santen's Values, the Santen Group will continue to actively play our role as a corporate citizen promoting a sustainable society, by contributing to the protection and improvement of eyesight and health as a specialized ophthalmic pharmaceutical company and by promoting CSR initiatives integrated with Santen's business conduct.

Santen Pharmaceutical Co., Ltd.

Christopher Hohman, General Manager, Corporate Communications Group E-mail: ir@santen.com Tel: +81-6-4802-9360

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, marketing, and sales of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in approximately 60 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen's website (www.santen.com).